Femme et Homme | Entre 18 ans et 130 ans
- | Pays :
- France
- | Organes :
- Vessie
- | Spécialités :
- Immunothérapie - Vaccinothérapie
- Chimiothérapie
Extrait
A phase III, randomized, open-label, multi-center, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer.